Befar (Topical Alprostadil Cream/ Alprox TD )

Befar 250mg has been discontinued by the manufacturer.

Befar Alprostadil Cream incorporates alprostadil (or prostaglandin E1), an off-patent drug that is well recognized for treating ED, with the NexACT technology. NexMed announced positive top-line results from its two pivotal Phase 3 studies of Alprox-TD cream treatment for erectile dysfunction ("ED"). The clinical data indicated that the three dose levels of Alprox-TD tested were effective over placebo in each study and in the combined analysis of the two studies. All doses showed a highly significant (p= 0.001 or p 0.001) increase in Erectile Function Domain scores using the International Index of Erectile Function (IIEF), the gold standard for measuring efficacy in ED products. The side effects reported were mostly mild to moderate, localized and transient. The overall discontinuance rate due to side effects was less than 4%.

Over 1,700 patients with mild to severe ED were enrolled in the two pivotal Phase 3 studies. The studies, conducted at 85 US research clinics, were randomized, double-blind, placebo-controlled, and were designed to confirm the efficacy and safety of Alprox-TD in patients with mild to severe ED. Alprox-TD incorporates alprostadil with NexMed's patented NexACT technology. The studies included patients who had not previously taken ED medications as well as patients who had little or no success with the currently approved oral medications for ED. Many of these patients also had diabetes, prostatectomies, hypertension and other serious medical conditions.

[Click here to view animation]